Hemophilia of Georgia outlines services, 340B participation and telehealth expansion to committee

Michelle Condie, senior director of advocacy for Hemophilia of Georgia, told the committee the nonprofit has served the state for more than 50 years and participates in the 340B program to support patients with bleeding disorders.

Condie said Hemophilia of Georgia treats about 2,000 patients in the state and that a typical annual cost of care for a person with a bleeding disorder can range from $300,000 to $500,000 in a healthy year; costs can exceed $1 million if complications occur. The organization uses 340B pharmacy revenue, plus grant and program dollars, to help patients pay for medications, premiums, deductibles, copayments and other needs through programs the speaker identified as CAP (client assistance program) and IPAP (insurance premium assistance program).

Condie described five hemophilia treatment centers around the state (Atlanta, Augusta, Savannah plus two hybrid/telehealth sites) and said the organization receives roughly $400,000 a year from the state Department of Public Health to support premium and deductible assistance. She said telehealth and hybrid sites, created in 2021, have brought many patients back into care and reduced unmet needs from rural areas.

The presentation emphasized family camps, mentoring for self‑infusion, nursing and social‑work outreach, and the organization’s role leading the Southeast Regional Hemophilia Network, which administers 340B grants across multiple states. Condie asked lawmakers to support policies that protect the 340B program, expand telehealth and address mental‑health and equity issues in the rare‑disease community.